<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Denileukin diftitox plus rituximab was evaluated in relapsed/refractory B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Of the 38 evaluable patients, 30 (80%) were rituximab-refractory </plain></SENT>
<SENT sid="2" pm="."><plain>The overall response rate (ORR) was 32%, with six complete responses (CR) and six partial responses (PR) </plain></SENT>
<SENT sid="3" pm="."><plain>The median time to progression for responders was 8 months (range: 2-36+); two patients with rituximab-refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were in CR at 25 and 36+ months </plain></SENT>
<SENT sid="4" pm="."><plain>The ORR was 55% (4 CRs, 2 PRs) in 11/14 patients with rituximab-refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and 100% in the three patients with rituximab-sensitive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Most toxicities were low grade and transient, and myelotoxicity was uncommon </plain></SENT>
</text></document>